← Food Handbook
XXIII.3

3. Microbial target index

Reverse view — the 196 foods organized by the eight most important microbial targets, ranked by level of evidence.

Function: cross-index to the 196 chaptersGoal: clinical decision supportEvidence: ★★ ★★★ scale + ⚠ riskSource: human RCTs, meta-analyses
🎯 What is this appendix for?

The Food Sources v1.5 book provides a per-food, in-depth description across its 196 chapters. This appendix offers the reverse view: it organizes the foods by microbial targets. A clinician, dietitian or donor-diet planner can thus get a quick answer to the question of which chapters contain the best foods for achieving a given target.

The appendix presents eight ranked lists by target. Only those foods are included for which the Food Sources v1.5 references contain at least moderate-strength evidence (★★). Entries at the ★ level (preclinical / hypothetical only) and empty cells are omitted — for the sake of credibility.

📊 Notation system
NotationInterpretation
★★★Strong human evidence: at least 1 RCT or meta-analysis with direct microbiome measurements
★★Moderate evidence: human pilot + mechanistic rationale + in vitro fermentation + epidemiological association
Risk category: control or dosing required (not an absolute contraindication)

The ★ and empty rows are omitted. The full 196-chapter evidence matrix is detailed within the individual chapters of the book.

1. Bifidobacterium support

What does it target? Fructan, FOS, GOS, inulin prebiotics → selective increase in the Bifidobacterium proportion in the colon.

★★★ — Strong human RCT evidence:

ChapterEvidence
I.1 ArtichokeCostabile 2010 Br J Nutr — human RCT with very-long-chain inulin
I.3 AsparagusTang 2015 human mid-FOS intake + EFSA inulin claim
I.4 ChicoryLink + Kolida 2002 Br J Nutr
I.14 Jerusalem artichokeBonnema 2010 J Am Diet Assoc + Tuohy 2001 human inulin RCT
XIII.4 Agave inulinRamnani 2015 J Nutr Sci + Camacho-Díaz 2023 Nutrients IBS-C RCT

★★ — Moderate evidence:

ChapterEvidence
I.5 OnionTang 2015 human mid-FOS association
I.6 GarlicSun 2017 human pilot + epidemiology
I.7 LeekFOS content + epidemiology
II.1 LentilGOS content + Bazzano 2011 meta + human intervention
II.2 ChickpeaFiber prebiotic + human legume-consumption meta
II.3 BeanGalactomannan fiber + epidemiology
II.4 Green pea / pea fiberHuman fiber-prebiotic pilots
III.2 AlmondLiu 2014 human RCT J Funct Foods
IV.1 AppleCuervo 2014 human pilot + pectin
IV.7 Green bananaBhattacharyya 2016 human RS2 pilot
V.2 DateEid 2014 in vitro + Eid 2015 human pilot
X.4 Chicory coffeeChicory inulin residue + Slavin meta
X.10 Chicory root teaCherbut 2002 + Kolida 2007 5—8 g inulin human
XIII.1 PsylliumJalanka 2019 Sci Rep human + F. prausnitzii increase
XIII.3 Gum arabicCalame 2008 Br J Nutr human RCT
2. Lactobacillus support

What does it target? Intake of live Lactobacillus / Lactiplantibacillus / lactic acid bacteria via fermented carriers.

★★★ — Strong human RCT evidence:

ChapterEvidence
VIII.1 SauerkrautWastyk 2021 Cell 10-week fermented-food portfolio RCT
VIII.3 KimchiHan 2015 Mol Nutr Food Res + Kim 2022 IBS RCT
IX.1 YogurtEFSA 2010 lactose-digestion claim + Marteau 2002 Aliment Pharmacol Ther DN-173 010
IX.2 KefirBellikci-Koyu 2019 Nutrients metabolic syndrome RCT + Wastyk 2021

★★ — Moderate evidence:

ChapterEvidence
VIII.2 Brined cucumberExtrapolated from the Wastyk portfolio
VIII.4 MisoInoue 2021 Nutrients 14-day human intervention
VIII.8 Fermented mixed vegetablesExtrapolated from the Wastyk portfolio
IX.3 Aged cheesesSharp 2008 J Dairy Sci probiotic Gouda elderly RCT
XV.28 KombuchaWastyk 2021 portfolio + Stiemsma 2020 J Nutr review
3. Akkermansia support

What does it target? Polyphenols, ellagitannins, anthocyanins → support of the Akkermansia muciniphila mucin matrix.

★★★ — Strong human RCT evidence:

ChapterEvidence
IV.4 PomegranateHenning 2017 Eur J Nutr + Cortés-Martín 2018 Front Microbiol ellagitannin–Akkermansia human RCT
X.1 Green tea / MatchaLink + Liu 2022 Crit Rev Food Sci Nutr review
XVI.1 Cacao / dark chocolateTzounis 2011 AJCN + COSMOS trial Sesso 2022 AJCN (n≈21,000)

★★ — Moderate evidence:

ChapterEvidence
III.1 WalnutHolscher 2018 J Nutr human microbiome RCT
III.3 PistachioUkhanova 2014 Br J Nutr human RCT + Bifidobacterium increase
IV.5 GrapeRoopchand 2015 Diabetes + Most 2017 AJCN human pilot
IV.11 BlackcurrantWallace 2016 Crit Rev Food Sci Nutr meta-analysis on anthocyanins
IV.12 CranberryAnhê 2015 Gut animal + Rodríguez-Morató 2018 human pilot
IV.13 Black chokeberry (aronia)Le Sayec 2022 Mol Nutr Food Res human RCT on anthocyanins
IV.14 BlueberryVendrame 2011 J Agric Food Chem + Lacombe 2013 J Funct Foods human
VII.17 Black riceCzank 2013 AJCN cyanidin-3-glucoside metabolism + Wallace 2016
X.2 Black teaMou 2018 Food Funct human RCT Prevotella + theaflavin
X.3 CoffeeJaquet 2009 Int J Food Microbiol + Asnicar 2024 Nat Med (n>22,000)
X.5 Pu-erh teaHou 2021 mSystems human microbiome module
XI.1 Extra virgin olive oilMarcelino 2019 Front Nutr review + Carnevale 2017 human pilot
XII.2 Mussel / oysterLink — diet–microbiome association
XV.1 TurmericScazzocchio 2020 Nutrients mechanistic + human microbiome module
XV.6 Chili / capsaicinKang 2017 mBio + Bonaccio 2019 JACC CV epidemiology
XIX.1 Broccoli sproutEgner 2011 Cancer Prev Res sulforaphane bioavailability human RCT
4. Butyrate production

What does it target? Roseburia, Faecalibacterium prausnitzii, Eubacterium rectale SCFA substrates.

★★★ — Strong human RCT evidence:

ChapterEvidence
VII.1 OatsConnolly 2016 J Funct Foods + EFSA β-glucan claim + butyrate fermentation human
VII.14 Resistant starch RS2Maki 2012 J Nutr + Walker 2011 ISME J + Bodinham 2014 Endocr Connect + Li 2024 Nat Metab
XIII.1 PsylliumJalanka 2019 Sci Rep — selective F. prausnitzii increase + serum butyrate increase

★★ — Moderate evidence:

ChapterEvidence
I.1 ArtichokeInulin fermentation (secondary colonic butyrate)
I.3 AsparagusInulin fermentation
I.4 ChicoryInulin fermentation
I.14 Jerusalem artichokeInulin fermentation
II.1 LentilGalactomannan + GOS human fermentation
II.2 ChickpeaGalactomannan + GOS
II.3 BeanGalactomannan fermentation human
III.7 FlaxseedHu 2019 human + lignan-mediated microbiome module
IV.7 Green bananaBhattacharyya 2016 human RS2 pilot
V.1 PruneLever 2014 Clin Nutr + Hooshmand 2022 human
VII.2 BarleyDe Angelis 2015 Appl Environ Microbiol + Aoe 2017 Nutrients
VII.3 RyeVuholm 2018 J Nutr + Eriksen 2020 Br J Nutr human crossover
VII.4 WheatCostabile 2008 Br J Nutr AXOS human RCT
VII.7 CornWhisner 2016 J Nutr + Van den Abbeele 2018 Br J Nutr human
VII.15 Resistant starch RS3Sonia 2015 APJCN + Patterson 2020 J Acad Nutr Diet
5. Propionate production (metabolic regulation)

What does it target? Bacteroidetes-mediated propionate production → GLP-1, PYY, appetite regulation, reduction of liver fat.

The human propionate-specific RCT evidence is more modest than for butyrate — therefore there is no ★★★ rating here. Propionate always appears in a butyrate + propionate matrix in human fermentation studies.

★★ — Moderate evidence:

ChapterEvidence
VII.1 OatsWolever 2010 AJCN — β-glucan + propionate human fermentation
VII.2 Barleyβ-glucan + propionate human fermentation
II.1 LentilGalactomannan + Bazzano 2011 lipid meta (indirect)
II.4 Green pea / pea fiberLupin/pea fiber prebiotic + human pilot
II.5 Lupin seed / lupin fiberLupin fiber specific propionate fermentation human
XIII.1 PsylliumGibb 2015 AJCN meta + propionate fermentation
IV.1 ApplePectin → propionate fermentation human
6. Oral nitrate—NO axis

What does it target? Dietary nitrate → Veillonella / Rothia / oral commensals nitrate reduction → nitrite → systemic NO → blood pressure, vascular function, athletic performance.

★★★ — Strong human RCT evidence:

ChapterEvidence
I.11 BeetrootLink + Velmurugan 2016 AJCN human hypertension RCT
I.18 SpinachBondonno 2016 nitrate-rich vegetables + flow-mediated dilation human

★★ — Moderate evidence:

ChapterEvidence
I.8 Cruciferous vegetablesModerate nitrate + Bondonno portfolio
I.13 RadishNitrate content + human pilot studies
7. Bilophila / bile-acid load risk

What does it indicate? Bilophila wadsworthia proliferates with high animal fat (especially saturated) + high taurine-conjugated bile-acid intake. A chronically high proportion is pro-inflammatory and colitis-associated. A risk requiring control, not an absolute contraindication.

⚠ — Risk category (each is high animal fat or high SFA):

ChapterEvidence
XI.2 ButterSaturated fat + Astrup 2020 AJCN matrix-hypothesis context
XI.3 GheeMore concentrated saturated fat (≈ 60 g SFA / 100 g)
XI.6 Coconut oil82—92% SFA + Sacks 2017 Circulation AHA advisory
XII.1 Fatty marine fishHigh total fat matrix consideration (context-sensitive)
XII.5 HerringHigh fat
XII.6 SardineHigh fat + Mortensen 2014 Q-SYMBIO context
XII.7 Tuna (fatty species)High fat + mercury dual risk
XII.8 SalmonHigh fat (context-sensitive)
XII.10 MackerelHigh fat
XII.13 EelHigh fat (≈ 18 g/100 g) + retinol stringency
XVII.1 Chicken eggCholesterol + choline-TMAO microbiome pathway — context-sensitive
XVII.4 Duck / goose eggHigher cholesterol (≈ 850 mg/100 g)
IX.3 Aged cheesesSaturated fat + tyramine combined risk
8. Methanogen / FODMAP / SIBO risk

What does it indicate? High fructan, GOS, raffinose, fructose or sorbitol is the gas-producing substrate of Methanobrevibacter smithii + Methanosphaera. In IBS- / SIBO-sensitive individuals it causes symptomatic worsening. It can be dosed (5—10 g/day start, titration), but control is required.

⚠ — Risk category (high FODMAP / fermentable substrate):

ChapterEvidence
I.1 ArtichokeHigh fructan (Monash red)
I.3 AsparagusFructan + raffinose
I.4 ChicoryInulin (12 g already at the IBS-symptom threshold)
I.5 OnionFructan Monash red
I.6 GarlicFructan Monash red
I.7 LeekFructan red
I.14 Jerusalem artichokeInulin (one of the highest natural sources)
II.1 LentilGOS + raffinose
II.2 ChickpeaGOS + raffinose
II.3 BeanGOS + raffinose Monash red
IV.19 Fresh figHigh fructose
V.1 PruneSorbitol + fructose concentrate
V.2 DateHigh fructose + glucose
V.3 RaisinHigh fructose + glucose concentrate
XIII.4 Agave inulinBranched fructan Monash red (12 g/day → IBS symptom)
🔍 How to use the appendix?

Clinical decision-making: Choose a target (e.g. "strong Akkermansia support"), look up the ★★★ list, and from there every food is ranked, with evidence. The contraindication matrix (Appendix B) can further filter for an individual patient.

Donor-diet planning: For weekly rotation, choose 2—3 foods from each target in the ★★★ group. Diversity supports not only taste but also the microbiome response.

Risk management: The ⚠ marking is not a ban but a question of dosing. In IBS / SIBO cases, titrate the items in list 8 starting at 5 g/day, gradually increasing over 2—4 weeks.

Updating with new evidence: The tables are dynamic — as new RCTs appear, the evidence levels are updated. They reflect the state of the v1.5 edition as of 2026-06-02.

📌 Audit criteria

The classification was carried out according to strict audit criteria developed during the internal review of Food Sources v1.5:

  • 7a) Journal-attribution accuracy: PMC, Wikipedia and other indexing / popular sources are NOT considered peer-reviewed sources.
  • 7b) Context match: the cited RCT applies to the food-specific form being examined (e.g. chicory inulin ≠ artichoke VLCI, garlic ≠ black garlic).
  • 7c) Prohibition of non-peer-reviewed sources: only peer-reviewed journals, EFSA / EMA / Cochrane / WHO / FDA official documents may be included.
  • 7d) Year consistency: the year in the text and the reference number must match.
  • 7e) Meta vs RCT disambiguation: a meta-analysis cannot be cited as an individual RCT.

If a statement does not meet the above criteria, the food is omitted from the list or assigned a lower evidence level. In the full review of the 196 chapters, 33 genuine factual errors and 54 attribution inconsistencies were corrected for the v1.5 version (see `SCI-REVIEW-FIXES.md`).


PG
Food Handbook · Authors: Dr. Patay Gábor — physician, microbiota specialist · Dr. Bezzegh Attila — medical director, clinical microbiologist · Dra. Anna Munar — physician, exposome specialist
MicroBiome Bank — medically reviewed professional content. Last updated: 2026.